Close

anti-vesicular stomatitis virus octapeptide (VSV8) (aa 52-59) TCR, pCDTCR1 (TCR-L120Z)

The vector of anti-vesicular stomatitis virus octapeptide (VSV8) T cell receptor (TCR) is constructed for the engineering of T cell to target VSIV vesicular stomatitis virus octapeptide (VSV8). The T cells are genetically modified through transduction with a retroviral vector expressing vesicular stomatitis virus octapeptide (VSV8)-specific T cell receptor.

Details

  • Target
  • VSV8
  • Target Species
  • VSIV
  • Epitope
  • RGYVYQGL
  • Format
  • Non-modified
  • Targeting Diseases
  • VSV Infection
  • Vector Name
  • pCDTCR1
  • Vector Length
  • 8kb
  • Vector Type
  • Lentiviral
  • Antibody Host
  • Human

Target

  • Gene Name
  • vesicular stomatitis virus octapeptide
  • Official Symbol
  • VSV8
  • Synonyms
  • VSIV8; VSIV-8; Vesicular Stomatitis Virus Nucleoprotein (52-59); Vesicular Stomatitis Virus Nucleoprotein
  • Introduction
  • This octapeptide is amino acids 52 to 59 fragment of the the vesicular stomatitis virus (VSV) nucleoprotein. VSV-8 is derived from the VSV nucleoprotein that is expressed in the cytosol of the infected cells. CTL response against VSV in H-2Kb mice is directed against this single VSV-8 immunodominant peptide. This peptide forms complex with murine MHC class I molecule H-2Kb, which is similar to human HLA class I.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry
Products

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.